10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates

分组1 - 10x Genomics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and improved from a loss of $0.40 per share a year ago, resulting in an earnings surprise of +31.58% [1] - The company achieved revenues of $166.03 million for the quarter ended December 2025, slightly surpassing the Zacks Consensus Estimate by 0.01%, and showing a year-over-year increase from $165.02 million [2] - 10x Genomics has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance in earnings expectations [2] 分组2 - The stock has gained approximately 17.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for investors, as it reflects current consensus earnings expectations and any recent changes in those expectations [4] - The estimate revisions trend for 10x Genomics was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] 分组3 - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $142.23 million, and for the current fiscal year, it is -$0.88 on revenues of $609.12 million [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]